Panretin

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1998-2005
01219982005

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2005
2005
Alitretinoin (9-cis-retinoic acid) is an FDA-approved topical therapy for the treatment of Kaposi sarcoma. Alitretinoin is a… (More)
Is this relevant?
2002
2002
Rexinoids binding to both the retinoic acid receptor (RAR) and retinoid X receptor (RXR) families of rexinoid receptors have… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table 1
Is this relevant?
2002
2002
OBJECTIVE To assess the efficacy, safety and tolerance of oral 9-cis-retinoic acid in HIV-infected patients with Kaposi's sarcoma… (More)
Is this relevant?
Review
2001
Review
2001
This review focuses on the use of alitretinoin (Panretin) gel 0.1% therapy as a new topical treatment of cutaneous lesions in… (More)
Is this relevant?
2000
2000
OBJECTIVE To evaluate the efficacy and safety of topical alitretinoin gel (9-cis-retinoic acid [LGD1057], Panretin gel; Ligand… (More)
Is this relevant?
Review
2000
Review
2000
Kaposi's sarcoma (KS) is the most common malignancy associated with the acquired immunodeficiency syndrome (AIDS). Recent years… (More)
Is this relevant?
1999
1999
BACKGROUND Kaposi's sarcoma (KS) is the most frequent malignancy in patients with HIV. Given the promise that retinoids show in… (More)
Is this relevant?
1999
1999
Ligand Pharmaceuticals has received FDA approval for Panretin Gel (alitretinoin) for topical treatment of Kaposi's sarcoma. The… (More)
Is this relevant?
1999
1999
  • The oncologist
  • 1999
 
Is this relevant?
1998
1998
Retinoids are compounds that bind to and activate one or more retinoid receptors to elicit various physiological responses. There… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 5
  • figure 4
Is this relevant?